BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC

BERGEN, Norway, Sept. 5, 2018 /PRNewswire/ — BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in…

Source: https://www.prnewswire.com:443/news-releases/bergenbio-to-present-interim-phase-2-clinical-data-with-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-at-wclc-300706904.html